News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCI/bupropion HCI) Extended-Release Tablets, which is approved in the United States. Orexigen’s partner for North America, Takeda Pharmaceuticals, markets CONTRAVE in the United States.

Outside of North America, Orexigen's strategy for naltrexone HCI /bupropion HCI is to purMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.67
Change (%) Stock is Up 0.11 (1.98%)
Volume4,897,415
Jan 27, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
01/08/15Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare ConferencePrinter Friendly Version
12/19/14Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European UnionPrinter Friendly Version
11/26/14Orexigen Therapeutics to Present at the Piper Jaffray Healthcare ConferencePrinter Friendly Version
11/21/14Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.